Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension. The positive topline results from the Phase 2 PHocus trial of Mosliciguat provide an important clinical validation for one of the company's most promising pipeline assets. The candidate drug produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD), substantially exceeding the 20% reduction threshold that Leerink Partners analyst David Risinger had identified as an important benchmark. The drug also produced a 35.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.